成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Annals of Pharmacotherapy >>article
Annals of Pharmacotherapy

Annals of Pharmacotherapy

IF: 2.29
Download PDF

Isavuconazole: A New Option for the Management of Invasive Fungal Infections.

Published:1 July 2015 DOI: 10.1177/1060028015581679 PMID: 25940222
Natasha N Pettit, Peggy L Carver

Abstract

Objective: To review the pharmacology, chemistry, in vitro susceptibility, pharmacokinetics, clinical efficacy, safety, tolerability, dosage, and administration of isavuconazole, a triazole antifungal agent.

Data sources: Studies and reviews were identified through an English language MEDLINE search (1978 to March 2015) and from http://www.clinicaltrials.gov, Food and Drug Administration (FDA) briefing documents, program abstracts from international symposia, and the manufacturer's Web site.

Study selection and data extraction: All published and unpublished trials, abstracts, in vitro and preclinical studies, and FDA briefing documents were reviewed.

Data synthesis: Isavuconazole has activity against a number of clinically important yeasts and molds, including Candida spp, Aspergillus spp, Cryptococcus neoformans, and Trichosporon spp and variable activity against the Mucorales. Isavuconazole, available for both oral and intravenous administration, is characterized by slow elimination allowing once-daily dosing, extensive tissue distribution, and high (>99%) protein binding. The most commonly reported adverse events, which are mild and limited in nature, include nausea, diarrhea, and elevated liver function tests. Its drug interaction potential appears to be similar to other azole antifungals but less than those observed with voriconazole. Comparative trials are under way or have been recently completed for the treatment of candidemia, invasive candidiasis and aspergillosis, and rare mold infections.

Conclusions: Isavuconazole has a broad spectrum of activity and favorable pharmacokinetic properties, providing an advantage over other currently available broad-spectrum azole antifungals and a clinically useful alternative to voriconazole for the treatment of invasive aspergillosis. It may also prove useful for the treatment of candidemia and invasive mold infections; however, these indications await the results of clinical trials.

Substances (6)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Voriconazole 137234-62-9 C16H14F3N5O 687 suppliers $9.00-$2250.00
Isavuconazole 241479-67-4 C22H17F2N5OS 340 suppliers $15.00-$1800.00
CRYPTOCOCCUSNEOFORMANS 6 suppliers Inquiry
CANDIDASPP 6 suppliers Inquiry
ASPERGILLUSSPP 4 suppliers Inquiry
Proteus spp antibody 3 suppliers Inquiry

Similar articles

IF:2.8

Role of isavuconazole in the treatment of invasive fungal infections.

Therapeutics and Clinical Risk Management Dustin T Wilson, V Paul Dimondi,etc Published: 3 August 2016
IF:13

Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis

Drugs M. Shirley,?L. Scott,etc Published: 20 October 2016
IF:3.5

Clascoterone: a new topical anti-androgen for acne management

International Journal of Dermatology Parvathy Santhosh MD, Mamatha George MD,etc Published: 9 July 2021